Johnson & Johnson Announces Positive Phase 1 Results for Prostate Cancer Treatment JNJ-6143
JNJ Johnson & Johnson
$267.14 -2.04%
View chart & analysis → - 1Johnson & Johnson paid $3.05 billion to acquire Halda Therapeutics last year.
- 2JNJ-6143 recorded a 75% overall response rate among patients with measurable disease in the Phase 1 clinical trial.
- 3The Phase 1 results for JNJ-6143 are very encouraging, demonstrating the strength of Johnson & Johnson's pipeline.
So what's the key point?
Johnson & Johnson paid $3.05 billion as the acquisition price for Halda Therapeutics last year.
Source The Motley Fool +1 · View original ↗
Nothing hidden: past picks and how they did against the S&P 500.